Asymchem Inaugurates Its First European Small Molecule Development and API Pilot Plant Manufacturing Site at Discovery Park in Sandwich, Kent, UK
Asymchem Appoints Dr. Cheng Yi Chen as CTO of Small-Molecule Sector
Chinese CDMO Asymchem takes over former Pfizer site in UK
Asymchem Laboratories (Tianjin) Co. Ltd., a CDMO serving the global pharmaceutical and biotech industry, has opened a new site in Woburn, Massachusetts.
Asymchem Announces Opening of R&D site near Boston, Massachusetts
TEDA TIANJIN, P.R. China and SINGAPORE, Oct. 20, 2022 /PRNewswire/ -- Asymchem (stock code: 002821.SZ), a leading global contract development and manufacturing service provider, and AUM Biosciences (AUM), a global clinical stage biotech company, focused on discovering, acquiring and developing next generation targeted oncology therapeutics, jointly announced today the completion of their first GMP production campaign of AUM601.
Asymchem Begins Construction in Taixing city, further Enhancing Small Molecule CDMO Business
Asymchem Labs, a Chinese CDMO, is in the early phases of planning (PDF) a 4 billion Chinese yuan to 5 billion Chinese yuan ($557 million to $697 million) manufacturing campus on the outskirts of Shanghai.
WALTHAM, Mass., Sept. 9, 2022 /PRNewswire/ -- Snapdragon Chemistry today announced that the previously announced acquisition by Asymchem will not proceed. Snapdragon and Asymchem were unable to agree to mitigation terms that would satisfy the U.S. Treasury's Committee on Foreign Investment in the United States (CFIUS).
Cambrex announced the completion of a $50 million expansion of API manufacturing capabilities at its flagship Charles City, Iowa facility. The two-year project increased the capacity of the API facility by 30 percent.